Oxidative stress and persistent pulmonary hypertension of the newborn treated with inhaled nitric oxide and different oxygen concentrations.
OBJECTIVE
The aim of this study was to determine the effects of inhaled NO with different oxygen concentrations on the inflammatory cascade in newborns with hypoxic respiratory failure secondary to persistent pulmonary hypertension.


METHODS
60 newborns received iNO and 30 of them received an initial oxygen concentration of 45% (group 1), while the other 30 newborns received an initial oxygen concentration of 80% (group 2). The levels of inflammatory cytokines (IL-6, IL-8, TNF-α) were measured. The clinical outcome was also recorded.


RESULTS
The findings show that interleukin concentrations (IL-6, IL-8, TNF-α) were significantly decreased between 0 and 72 hours (p < 0.01) in the newborns exposed to initial oxygen concentration of 45% and significantly increased in the other group.


CONCLUSIONS
When inhaled, NO was co-administered with concentration of O(2) <45%, anti-inflammatory responses occurred, in accord with evidence in the published literature. The benefits of iNO on the clinical outcome in the current study demonstrate that inhaled NO in both groups was associated with improved short-term oxygenation.
Department of Pediatrics, Neonatal Intensive Care Unit, University of Messina, Messina, Italy. egitto@unime.it
Eloisa
E
Gitto
Salvatore
S
Pellegrino
Salvatore
S
Aversa
Carmelo
C
Romeo
Giuseppe
G
Trimarchi
Ignazio
I
Barberi
Maria Pia
MP
Calabró
Carmelo Damiano
CD
Salpietro
Russell J
RJ
Reiter
D000280:Administration, Inhalation; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008297:Male; D009569:Nitric Oxide / Q000008:administration & dosage*; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology; D010100:Oxygen / Q000008:administration & dosage*; D010547:Persistent Fetal Circulation Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D012121:Respiration, Artificial / Q000379:methods; D012127:Respiratory Distress Syndrome, Newborn / Q000097:blood / Q000150:complications / Q000628:therapy; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D015850:Interleukin-6; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D010100:Oxygen